Cancer Prevention II by Hans-Jörg SennCancer Prevention II by Hans-Jörg Senn

Cancer Prevention II

EditorHans-Jörg Senn, Ursula Kapp, Florian Otto

Hardcover | December 10, 2008

not yet rated|write a review

Pricing and Purchase Info

$310.95

Earn 1555 plum® points

In stock online

Ships free on orders over $25

Not available in stores

about

This Recent Results in Cancer Research volume contains the majority of the invited expert contributions of the Fifth International Conference on Cancer Prevention, held 6-8 March 2008 at the University of St. Gallen, Switzerland. Written by some of the world's leading experts in the field, the volume constitutes a comprehensive update on the most important and recent developments in molecular biology and cancer genetics, regarding chiefly the upsurging, but still controversial, field of primary prevention, especially chemoprevention. This conference primarily addressed the four leading and most frequent solid tumor types - breast, colon, gynecological, and lung cancer - all of which demonstrate how such an approach is currently possible and important in clinical cancer prevention research. The future prospects of chemoprevention and the process of selecting the most successful target populations at risk are discussed.

Details & Specs

Title:Cancer Prevention IIFormat:HardcoverDimensions:272 pagesPublished:December 10, 2008Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3540692967

ISBN - 13:9783540692966

Look for similar items by category:

Customer Reviews of Cancer Prevention II

Reviews

Extra Content

Table of Contents

Cancer Prevention and Health Politics. Do we make optimal use of the potential of cancer prevention? Predictors of successful cancer prevention programs. Cancer prevention in the developing world: mission impossible?Is cancer prevention ever going to be profitable?.- Cancer Prevention: The Scientific-Epidemiological Base. Energy metabolism, cancer risk, and cancer prevention. Promises and limitations of biomarkers.- Cancer Prevention, Tobacco and Nutrition. The EPIC study: an update. Anti-angiogenic properties of chemopreventive drugs: Fenretinide as a prototype. Retinoids and breast cancer prevention.- Cancer Prevention, Genetics and Vaccines. Cancer prevention by vaccination against hepatitis B.- Cancer Prevention and Target Organs I: Breast Cancer. Energy restriction for breast cancer prevention. The use of Tamoxifen and Raloxifene for the prevention of breast cancer. Prevention of ER-negative breast cancer. Exogenous and endogenous hormones, mammographic density and breast cancer risk - can mammographic density be considered an intermediate marker of risk?.- Cancer Prevention and Target Organs II: Cancer of the Digestive Tract. Chemoprevention of oesophageal cancer and the AspECT trial.- Cancer Prevention and Target Organs III: Prostate Cancer. Review of diagnostic markers for prostate cancer. Selenium and vitamin E cancer prevention trial (SELECT): a nutrient approach to prostate cancer prevention. Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies.- Cancer Prevention: Metabolic Aspects. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids.- Aspirin and NSAIDs in Cancer Prevention: Attempts at an International Consensus. Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of asprin to prevent cancer. Aspirin and NSAIDs for the prevention of colorectal cancer. Aspirin and cancer risk: a summary review.